Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

Multicenter, Open, Prospective, 48 Weeks, Observational Study ,Evaluate the Safety and Efficacy of Nephoxil Capsule

← catalyst calendar

NCT06206135 · readout in 542 d

Sponsored by LG Chem (industry) · 051910.KS — their whole pipeline →.

Phase
Status
Recruiting
Study type
Observational
Enrollment
172estimated
Sites
1
Country
South Korea

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-09-03

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2023-12-21actualWhen the study began enrolling
Primary completion2028-02-28estimatedThe date the last participant is measured for the primary outcome — the readout window
Study completion2028-12-31estimatedThe whole study's end, after follow-up
First posted2024-01-16actualWhen this record first appeared on the registry
Results postedWhen the sponsor posted results to the registry
Record updated2026-09-03actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

  • Hyperphosphatemia

Intervention

  • Drug: the low-dose group (1.5 g/day) or the standard-dose group (4 g/day)

Primary outcome

what the primary-completion date above is the date OF
Ratio of reached target serum phosphorus level (3.5 - 5.5 mg/dL) at week 48
measured 48 weeks

Permalink · 051910.KS's whole pipeline · Catalyst calendar · Every registered study · What changed